EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway

Jing Lv, Shengkai Jin, Yuhua Zhou, Chaowei Fu, Yang Shen, Bo Liu, Jufa Li, Menglu Li, Yuwei Zhang, Ninghan Feng

Frontiers in Pharmacology · 11.03.2025 · 16

DOI: 10.3389/fphar.2025.1528058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.03.2025. Verfasst von Jing Lv und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer is one of the most common malignant tumors among men worldwide, and current treatments still face many challenges. Therefore, researchers are continuously seeking new therapeutic methods to improve treatment efficacy and reduce side effects. Phenylacetylglutamine (PAGln), a common metabolite of the gut microbiota, has been reported to have anti-inflammatory and anti-tumor activities.

Methods

We assessed the impact of PAGln on prostate cancer using in vitro and in vivo models. Cell proliferation, migration, and invasion capabilities were evaluated through CCK8, EdU incorporation, and colony formation assays, as well as wound healing and Transwell assays. The in vivo anti-cancer effects of PAGln were evaluated using a BALB/c nude mouse xenograft model of prostate cancer and a lung metastatic tumor model established via tail vein injection. Molecular mechanisms were investigated through qRT-PCR and Western blot analysis.

Results

PAGln inhibited the proliferation, migration, and invasion of prostate cancer (PCa) cells in vitro and suppressed the growth of prostate cancer in vivo . PAGln notably increased the mRNA levels of CCNG2 in PCa cells. Importantly, the knockdown of CCNG2 weakened the effects of PAGln on PCa cells. Mechanistic studies revealed that PAGln could promote the phosphorylation of β-catenin by upregulating CCNG2, thereby inhibiting the Wnt/β-catenin signaling pathway.

Conclusion

In summary, PAGln can effectively inhibit the proliferation, migration, and invasion of PCa by upregulating CCNG2 and suppressing the Wnt/β-catenin signaling pathway. These findings suggest that PAGln may serve as a promising therapeutic agent for prostate cancer.

Schlagwörter

Stichwörter der Autor:innen

CCNG2Wnt/β-catenin pathwaymigrationphenylacetylglutamineproliferationprostate cancer

Autor:innen und Institutionen

  • Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Department of Urology, Jiangnan University Medical Center, Wuxi, China.
  • Jiangnan Medical Center, Nanjing Medical University, Nanjing, China.
  • Medical School of Nantong University, Nantong, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lv, J., Jin, S., Zhou, Y., Fu, C., Shen, Y., Liu, B., Li, J., Li, M., Zhang, Y., & Feng, N. (2025). Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1528058

Vancouver

Lv J, Jin S, Zhou Y, Fu C, Shen Y, Liu B, et al. Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1528058

BibTeX
@article{Lv2025,
  author = {Lv, Jing and Jin, Shengkai and Zhou, Yuhua and Fu, Chaowei and Shen, Yang and Liu, Bo and Li, Jufa and Li, Menglu and Zhang, Yuwei and Feng, Ninghan},
  title = {Gut microbiota-derived metabolite phenylacetylglutamine inhibits the progression of prostate cancer by suppressing the Wnt/β-catenin signaling pathway},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1528058}
}
Kostenlos starten →